Warburg Pincus adds med tech entrepreneur-in-residence; Cardiac Dimensions tops up round to $28.5M;

@FierceMedDev: This week's issue of FierceDiagnostics is out! Sign up for free here. | Follow @FierceMedDev

@VarunSaxena2: Flowonix submits MRI-compatible implantable infusion pump for FDA approval. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Robot-assisted surgery often comes with more complications and higher costs, according to new study. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: From our Women in Biotech Feature: Adelene Perkins of $INFI says, "Our endeavor is by definition a team sport." More | Follow @MichaelGFierce

> Cardiac Dimensions, a company specializing in minimally invasive treatments for cardiovascular conditions, added $8.5 million to bring its latest venture round to a total of $28.5 million. Release

> Private equity firm Warburg Pincus appointed experienced med tech executive Dr. Richard Hassett as an executive-in-residence for its healthcare group. Release

> The FDA approved MOZART with TomoSpec, a breast specimen radiography system with tomosynthesis technology, created by Kubtec, developer of digital specimen radiography systems. Release

Biotech News

@FierceBiotech: New special report: Top 7 life sciences public investors. Feature | Follow @FierceBiotech

@JohnCFierce: BIA did a report on bio-fundraising in the U.K. Hard to see where the promo ends and the analysis begins. Very Yank. More | Follow @JohnCFierce

@DamianFierce:  | Follow @DamianFierce

@EmilyMFierce: Hmmm... Cancer tumours destroyed by berry found in Queensland rainforest. More from The Guardian | Follow @EmilyMFierce

> Buzz: Unsated by its Durata deal, Actavis looks again to buy Allergan. More

> Levicept emerges from Pfizer's R&D ashes with $20M and a new pain drug. Story

> Amgen declares a head-to-head PhIII win for Humira biosimilar. News

> Chimerix scores promising antiviral data from a controversy-fueled PhIII pilot. Article

Pharma News

@FiercePharma: Top-read special report in FP Tues: Top 10 pharma companies by employees - 2014. Feature | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bayer insists its probiotic marketing claims aren't full of hot air. Article | Follow @CarlyHFierce

> Novartis, GSK shake up executive ranks as overhaul continues. Article

> With Actavis poised to swoop in, Valeant eyes $4.5B hike in bid for Allergan. Report

Drug Delivery News

> Flat nanosheets roll drugs up and release them on command. Item

> With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells. More

> Flowonix submits MRI-compatible implantable infusion pump for FDA approval. Story

> USPTO to review delivery patent in spat between Suboxone and BDSI's Bunavail. Report

> Alnylam says it wants to enter larger disease areas using partnership-driven approach. More

Diagnostics News

> MD Anderson pursues two projects targeting personalized prostate cancer testing. News

> Health Diagnostic Laboratory helps find promising predictive diabetes biomarkers. More

> Swedes, Harvard and more find success with DNA test for Afib risks. Report

> NanoString and a Harvard-affiliated hospital hope to quicken creation of new cancer tests. Story

> Quest, in transition, recruits Mayo Clinic exec to run major division. Article

Pharma Marketing News

> Analysts: Actavis-Allergan deal could create a marketing superpower. Item

> Pfizer's new #viagracommercial lights up Twitter during MLB playoffs--and not in a good way. More

> Merck hops onto HBCU network to step up its brand in the African-American community. Report

> Hand out prizes for adherence? West and HealthPrize team up to test the idea. Story

> Balking at marketing slapdown, Galderma declares itself pharma non grata. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.